Sun Pharma warns US pricing pressure to hit 2019 profit

INSUBCONTINENT EXCLUSIVE:
expectations due to pricing pressure in its main market, the United States. Makers of generic drugs have seen poor sales as uncertainty
warning compounds problems at Sun, which has been struggling to get clearance for its factories that are under US supply bans due to quality
re-certified at the earliest
($4.43 billion) - about 13 percent higher than the 264.89 billion rupees for 2018. While fourth-quarter profit was better than expected,
helped by an uptick in India and emerging markets, revenue in the United States, which accounts for almost 35 percent of the total, fell 3
percent, Sun said. Rivals Dr